看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
4 m F- s2 q& N6 Q* ~/ b1 p3 o6 R' W0 b
+ ^+ \% Y, X2 n2 N/ p. d( hCurrently available feasibility data for possible combination strategies.
! K* Q3 l5 z# \————————————————————————————————0 `& Q8 j$ n- u& ~7 U; j. p e
Combination Feasibility according to preliminary data # Y! T4 g* K/ V, q/ q8 \
——————————————————————————————————! Z8 S4 V! ]- J6 Y7 I
Bevacizumab + sorafenib Yes, reduced dose # F3 c k$ r) q, T$ S& P
Bevacizumab + sunitinib† No
( X$ i) e; o- N7 \* A/ LBevacizumab + temsirolimus Yes
/ J: I+ T$ R9 R8 J( L+ }# P2 a. CBevacizumab + everolimus Yes * X, j% e* x; u6 n
Sorafenib + sunitinib ? 2 N7 M. m {" C1 v" R
Sorafenib + temsirolimus Yes, reduced dose 1 w' F7 v2 y% s/ o+ o5 u
Sorafenib + everolimus Yes, reduced dose
, G' U$ ^( c2 _Sunitinib + temsirolimus† No
4 x4 C) z/ N8 J" x9 [Sunitinib + everolimus ?
s( j( Q% Q/ B4 H8 xTemsirolimus + everolimus ?
) V! [. s) E& e: ^7 V; \————————————————————
: n6 d& a g# ^+ Q5 d/ ?! \†Led to US FDA warning.# U/ W+ c$ Y( d
?: As yet unattempted combination.
\& u- |6 r: ^& Q) i3 C |